Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...
Delve into the challenges Black Americans face with Alzheimer’s and the urgent need for better prevention, care, and ...
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...
Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...